《公司業績》石藥(01093.HK)半年純利23.14億人幣升23.2% 中期息6港仙 5送3紅股
石藥集團(01093.HK)公布截至今年6月底止中期業績,營業額125.9億元人民幣(下同),按年升12.6%。純利23.14億元,按年升23.2%;每股盈利30.97分。派中期息6港仙,上年同期不派息。建議按每持有5股現有股份,發行3股新股之基準發行紅股。
期內,毛利為94.4億元,按年升20.8%;經營溢利為26.2億元,按年增長11.9%。
按業務劃分,上半年成藥收入102.3億元,按年升16.7%;維生素C收入10.05億元,跌13.2%;抗生素收入跌10%至4.78億元;其它收入增21.1%至8.76億元。
於上半年,研發費用為14.5億元,按年增加54.2%,約佔成藥業務收入的14.2%。
集團指,目前在研項目300餘項,其中小分子創新藥40餘項、大分子創新藥50餘項,新型製劑20餘項,主要聚焦在腫瘤、自身免疫、精神神經、消化和代謝、心腦血管系統及抗感染治療領域。
目前有25個藥品處於註冊審評待批階段,42個產品正在開展臨床試驗(包括31個創新藥以及11個新型製劑),9個產品正在進行生物等效試驗,以及7個產品待批臨床批件(6個國內及1個美國)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.